Repurposing chlorpromazine to treat COVID-19: The reCoVery study

被引：69

作者：

Plaze, M. ^{[1
,2
]}

Attali, D. ^{[1
,2
,3
]}

Petit, A-C ^{[1
,4
]}

Blatzer, M. ^{[4
]}

Simon-Loriere, E. ^{[5
]}

Vinckier, F. ^{[1
,2
]}

Cachia, A. ^{[6
,7
]}

Chretien, F. ^{[4
,8
]}

Gaillard, R. ^{[1
,2
,4
]}

机构：

[1] Pole Hosp Univ Paris 15, GHU PARIS Psychiat & Neurosci, Site St Anne, Serv Hosp Univ, Paris, France

[2] Univ Paris, Paris, France

[3] Univ Paris Diderot, Phys Med Paris, INSERM, ESPCI Paris,CNRS,PSL Res Univ,Sorbonne Paris Cite, Paris, France

[4] Inst Pasteur, Expt Neuropathol Unit, Paris, France

[5] Inst Pasteur, G5 Evolutionary Genom RNA Viruses, Paris, France

[6] Univ Paris, Inst Psychiat & Neurosci Paris, INSERM, Paris, France

[7] Univ Paris, Lab Psychol Dev & Educ Enfant, CNRS, Paris, France

[8] GHU PARIS Psychiat & Neurosci, Serv Neuropathol, Site St Anne, Paris, France

来源：

ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE | 2020年 / 46卷 / 03期

关键词：

Chlorpromazine; SARS-CoV-2; COVID-19; Repurposing of molecules; Clinical trial; ANTIPSYCHOTIC-DRUGS; IL-10; PRODUCTION; TNF PRODUCTION; VIRUS; BRAIN; REPLICATION; BLOOD; CELLS; INHIBITION; INFECTION;

D O I：

10.1016/j.encep.2020.05.006

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Objectives. - The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity. Methods. - In this context, the ReCoVery study aims to repurpose CPZ, a molecule with an excellent tolerance profile and a very high biodistribution in the saliva, lungs and brain. We hypothesize that CPZ could reduce the unfavorable course of COVID-19 infection among patients requiring respiratory support without the need for ICU care, and that it could also reduce the contagiousness of SARS-CoV-2. For this purpose, we plan a pilot, multicenter, randomized, single blind, controlled, phase III therapeutic trial (standard treatment vs. CPZ + standard treatment). Conclusion. - This repurposing of CPZ for its anti-SARS-CoV-2 activity could offer an alternative, rapid strategy to alleviate infection severity. This repurposing strategy also avoids numerous developmental and experimental steps, and could save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easily managed side effects. (C) 2020 L'Encephale, Paris.

引用

页码：169 / 172

页数：4

共 41 条

[31]

SJOSTRAND SE, 1965, ARCH INT PHARMACOD T, V156, P34

[32]

TARAZONA R, 1995, J IMMUNOL, V154, P861

[33] DRUG DISTRIBUTION BETWEEN BLOOD AND BRAIN AS A DETERMINANT OF ANTIPSYCHOTIC DRUG EFFECTS [J].